Vistra Option Alert: Apr 11 $131 Puts Sweep (10) near the Ask: 599 vs 0 OI; Earnings 5/7 Before Open [est] 

Vistra Option Alert: Apr 11 $131 Puts Sweep (10) near the Ask: 599 @ $8.55 vs 0 OI; Earnings 5/7 Before Open [est] Ref=$130.0875

Vistra (NYSE:VST) Stock

VISTRA CORP

Vistra

Vistra Energy is one of the largest power producers and retail energy providers in the US. Following the 2024 Energy Harbor acquisition, Vistra owns 41 gigawatts of nuclear, coal, natural gas, solar, and energy storage assets. Its retail electricity business serves 5 million customers in 20 states, including almost a third of all Texas electricity consumers. Vistra emerged from the Energy Future Holdings bankruptcy as a stand-alone entity in 2016. It acquired Dynegy in 2018.

Vistra Corp

Vasta Platform Limited - Class A Ordinary Shares

Vasta Platform Ltd

VISION TECHNOLOGY CORP by Vision Technology Corp.

Vision Technology Corp

Vast Renewables Limited - Ordinary Shares

Vast Renewables Ltd

VNV Global AB

Verastem Inc

VISTA OUTDOOR INC COM

Vestis Corp

News

Stock Split

VEEE

Twin Vee PowerCats Announces 1-For-10 Reverse Stock Split, Effective April 7,2025

Commercial Vehicle Group, Inc. (the "Company" or "CVG") announced the retirement of Robert C. Griffin, from the Board of Directors of the Company, effective May 15, 2025, without standing for re-election at the 2025 annual meeting of stockholders.
Mr. Griffin has served as a Director since 2005 and is the current Chairman of the Board. Mr. Griffin's retirement is not as a result of any disagreement with the Company, its management, the Board or any committee of the Board. It is expected that William C. Johnson will serve as the Chairman of the Board following Mr. Griffin's retirement.

Management

CVGI

Commercial Vehicle Group Board Member Robert Griffin To Retire; William Johnson To Become Chairman Of The Board

Barclays analyst Manav Patnaik downgrades Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) from Overweight to Equal-Weight and lowers the price target from $325 to $260.

Downgrades

Price Target

Analyst Ratings

Barclays Downgrades Equifax to Equal-Weight, Lowers Price Target to $260

Mike Hansen to Retire as CFO at Fiscal Year-End
Scott Garula to Succeed Hansen as CFO
Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) today announced that Mike Hansen will retire from his role as Executive Vice President &amp; Chief Financial Officer (CFO) and transition to a new role as Assistant to the CEO, effective May 31, 2025. In this capacity, Hansen will support the transition to his successor and contribute to certain strategic initiatives and special projects. Scott Garula, currently President of Cintas' Rental Division, will succeed Hansen as Executive Vice President &amp; CFO.
Todd Schneider, Cintas President &amp; CEO, said, "Continuity of leadership is important, and this planned transition follows a thoughtful succession process. We have a tremendous bench of world-class leaders ensuring the right team is in place to guide our Company into the future.

CTAS

Cintas' Mike Hansen To Retire As CFO At Fiscal Year-End; Scott Garula To Succeed Hansen As CFO

Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)&nbsp;announced Thursday that it will offer new and existing customers a three-year price lock guarantee on all myPlan and <a target="_blank" href="https://www.benzinga.com/topic/verizon" rel="noreferrer noopener">myHome network plans</a>.
The deal builds on Verizon&#8217;s MyPlan and MyHome offerings, which allow customers to bundle streaming services, mobile phone service and home internet, including <a href="https://www.verizon.com/about/news/accelerating-customer-first-strategy-3-year-price-lock-and-free-phone" target="_blank" rel="noreferrer noopener">devices</a>.
Verizon previously offered free phones for its premium subscriber plans.&nbsp;Now, it is offering a free phone to new and existing customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/02/43883822/t-mobile-wins-nyc-public-safety-deal-introduces-new-plans-for-first-responders-and-military-families" rel="noreferrer noopener">T-Mobile Wins NYC Public Safety Deal, Introduces New Plans For First Responders And Military Families</a>
The users will need to trade in an old Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>), or Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google phone in any condition and be on a myPlan subscription.&nbsp;
Verizon Consumer CEO Sowmyanarayan Sampath said the three-year price lock across mobile and home provides peace of mind and a free phone on every myPlan, gives customers even more value.
The company will also offer free satellite-based text messaging to any myPlan subscriber on qualifying devices.
However, the three-year guarantee does not encompass fees and taxes, implying Verizon can still raise the monthly bill through increased fees,  cut the monthly autopay discount, or persuade consumers to migrate to a pricier plan with the offer of a new phone, The Verge <a href="https://www.theverge.com/news/642325/verizon-myplan-price-lock-three-years" target="_blank" rel="noreferrer noopener">reports</a>. 
Verizon and its peers&nbsp;AT&amp;T Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)&nbsp;and&nbsp;T-Mobile US Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) compete intensely for market share.
Since Sampath&nbsp;assumed charge in 2023, he has&nbsp;hiked prices&nbsp;and introduced flexible pricing plans to drive growth, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-03/verizon-offers-new-perks-to-woo-subscribers-in-tight-market?sref=TBDibEcD" rel="noreferrer noopener">reports</a>. Verizon has also added bundles that include access to <a target="_blank" href="https://www.benzinga.com/news/23/12/36071567/verizon-unveils-groundbreaking-10-streaming-deal-netflix-max-join-forces" rel="noreferrer noopener">streaming services such</a> as Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
T-Mobile&nbsp;<a target="_blank" href="https://www.benzinga.com/tech/25/02/43582884/elon-musks-spacex-and-t-mobile-go-live-with-starlink-powered-satellite-to-cell-service-heres-how-much-it-will-cost" rel="noreferrer noopener">plans to charge&nbsp;customers</a> $10-$15 monthly for SpaceX&#8217;s Starlink-supported text and data services.
Price Action: VZ stock is up 0.59% at $45.89 premarket on the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44639271/nvidias-custom-gpu-enhances-nintendo-switch-2-with-ai-features-real-time-ray-tracing-4k-support" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Custom GPU Enhances Nintendo Switch 2 With AI Features, Real-Time Ray Tracing, 4K Support</a></li>
</ul>
Photo: Shutterstock

Media

AAPL

GOOG

GOOGL

NFLX

SSNLF

TMUS

Verizon's New 3-Year Price Lock, Free Phone Offer: Strategic Move To Boost Customer Retention

In the preceding three months, 4 analysts have released ratings for G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.25, a high estimate of $32.00, and a low estimate of $25.00. A 12.69% drop is evident in the current average compared to the previous average price target of $33.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1743768074_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive G-III Apparel Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$25.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$30.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to G-III Apparel Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of G-III Apparel Group compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of G-III Apparel Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into G-III Apparel Group's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GIII/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on G-III Apparel Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About G-III Apparel Group</h2>
G-III Apparel Group Ltd is a textile company. It makes a wide range of apparel, footwear, and accessories that it sells under its own brands, licensed brands, and private-label brands. G-III has a substantial portfolio for licensed and proprietary brands, anchored by five global power brands: DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger, and Karl Lagerfeld. The company has two reportable operations: Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, as well as sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenues from Wholesale operations.
<h3>Breaking Down G-III Apparel Group's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining G-III Apparel Group's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 9.77% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: G-III Apparel Group's net margin excels beyond industry benchmarks, reaching 5.81%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): G-III Apparel Group's ROE stands out, surpassing industry averages. With an impressive ROE of 2.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): G-III Apparel Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.85%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GIII

A Glimpse Into The Expert Outlook On G-III Apparel Group Through 4 Analysts

Across the recent three months, 6 analysts have shared their insights on AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.67, a high estimate of $25.00, and a low estimate of $14.00. Observing a downward trend, the current average is 6.47% lower than the prior average price target of $23.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1743768066_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of AVITA Medical among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Brooks O'Neil</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AVITA Medical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of AVITA Medical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AVITA Medical's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RCEL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on AVITA Medical analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering AVITA Medical: A Closer Look</h2>
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
<h3>Understanding the Numbers: AVITA Medical's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, AVITA Medical showcased positive performance, achieving a revenue growth rate of 29.67% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: AVITA Medical's net margin excels beyond industry benchmarks, reaching -62.96%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): AVITA Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -138.57%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -14.42%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: AVITA Medical's debt-to-equity ratio is notably higher than the industry average. With a ratio of 10.22, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RCEL

6 Analysts Assess AVITA Medical: What You Need To Know

Throughout the last three months, 4 analysts have evaluated Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Orchestra BioMed Hldgs, revealing an average target of $14.5, a high estimate of $20.00, and a low estimate of $12.00. Experiencing a 9.38% decline, the current average is now lower than the previous average price target of $16.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1743768055_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Orchestra BioMed Hldgs by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Orchestra BioMed Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Orchestra BioMed Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Orchestra BioMed Hldgs's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Orchestra BioMed Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OBIO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Orchestra BioMed Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Orchestra BioMed Hldgs</h2>
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
<h3>A Deep Dive into Orchestra BioMed Hldgs's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Orchestra BioMed Hldgs faced challenges, resulting in a decline of approximately -3.44% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Orchestra BioMed Hldgs's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -6385.38%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Orchestra BioMed Hldgs's ROE excels beyond industry benchmarks, reaching -40.81%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Orchestra BioMed Hldgs's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -21.33%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.5, Orchestra BioMed Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Where Orchestra BioMed Hldgs Stands With Analysts

RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $66.00, and a low estimate of $17.00. Experiencing a 18.74% decline, the current average is now lower than the previous average price target of $44.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1743768045_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive RxSight. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$17.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$66.00</td>
<td>$66.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to RxSight. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of RxSight compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of RxSight's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into RxSight's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RXST/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on RxSight analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into RxSight's Background</h2>
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
<h3>RxSight: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: RxSight displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 40.71%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: RxSight's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -14.77% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): RxSight's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.13%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): RxSight's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -1.89%, the company showcases efficient use of assets and strong financial health.
Debt Management: RxSight's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.04.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RXST

Deep Dive Into RxSight Stock: Analyst Perspectives (12 Ratings)

JP Morgan analyst Jeffrey Zekauskas downgrades LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) from Overweight to Neutral and lowers the price target from $80 to $60.

JP Morgan Downgrades LyondellBasell Industries to Neutral, Lowers Price Target to $60

Analysts' ratings for Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Five9, revealing an average target of $55.25, a high estimate of $65.00, and a low estimate of $46.00. This upward trend is apparent, with the current average reflecting a 3.72% increase from the previous average price target of $53.27.
<img src="https://www.benzinga.com/files/images/story/2025/1743768027_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Five9 is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$46.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Five9. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Five9 compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Five9's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Five9's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FIVN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Five9 analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Five9</h2>
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
<h3>Five9: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining Five9's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.56% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Five9's net margin excels beyond industry benchmarks, reaching 4.15%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Five9's ROE stands out, surpassing industry averages. With an impressive ROE of 1.95%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.57%, the company showcases effective utilization of assets.
Debt Management: Five9's debt-to-equity ratio stands notably higher than the industry average, reaching 1.98. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FIVN

Where Five9 Stands With Analysts

Throughout the last three months, 5 analysts have evaluated Montrose Environmental Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEG#NYSE">MEG</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.6, a high estimate of $39.00, and a low estimate of $28.00. This current average has decreased by 9.18% from the previous average price target of $39.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1743768016_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Montrose Environmental Gr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Durgesh Chopra</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Montrose Environmental Gr. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Montrose Environmental Gr compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Montrose Environmental Gr's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Montrose Environmental Gr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MEG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Montrose Environmental Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Montrose Environmental Gr</h2>
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.
<h3>Key Indicators: Montrose Environmental Gr's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Montrose Environmental Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.07% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: Montrose Environmental Gr's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -16.38% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Montrose Environmental Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -6.92%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.1%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Montrose Environmental Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.63.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Montrose Environmental Gr's Future

JP Morgan analyst Jeffrey Zekauskas downgrades Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) from Overweight to Neutral and lowers the price target from $40 to $31.

JP Morgan Downgrades Dow to Neutral, Lowers Price Target to $31

JP Morgan analyst Robbie Marcus downgrades RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) from Overweight to Underweight and lowers the price target from $40 to $17.

JP Morgan Downgrades RxSight to Underweight, Lowers Price Target to $17

BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) shares are trading lower premarket on Friday. The company disclosed that its board has begun the process of selecting a <a href="https://www.bp.com/en/global/corporate/news-and-insights/press-releases/bp-chair-announces-intention-to-step-down-board-launches-search-for-successor.html" target="_blank" rel="noreferrer noopener">new </a>chair following Helge Lund's decision to step down.
The succession process, led by Dame Amanda Blanc as senior independent director with board support, aims to ensure a smooth transition.
The selected candidate will join the board and work alongside Helge Lund before officially assuming the chair role, likely in 2026.
Helge stated, "Having fundamentally reset our strategy, bp's focus now is on delivering the strategy at pace, improving performance and growing shareholder value. Now is the right time to start the process to find my successor and enable an orderly and seamless handover."
The decision follows pressure from activist hedge fund Elliott Management, which has been pushing for further changes at BP, reported Reuters.
Notably, in February, Elliott Management reportedly acquired a stake in BP and had been advocating for substantial changes at the British oil <a target="_blank" href="https://in.benzinga.com/news/large-cap/25/02/43591241/whats-going-on-with-oil-giant-bp-stock-today" rel="noreferrer noopener">company to boost its performance</a>.
In the same month, BP reported that it missed fourth-quarter revenue and earnings estimates, with hydrocarbon production <a target="_blank" href="https://www.benzinga.com/25/02/43618537/bp-q3-results-lower-revenue-rising-debt-but-175-billion-buyback-and-dividend-hike-impress" rel="noreferrer noopener">down 5.4% year-over-year</a>.
Investors can gain exposure to the stock via&nbsp;Precidian ETFs Trust BP plc ADRhedged&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/BPH#BATS">BPH</a>) and&nbsp;Texas Capital Funds Trust Texas Capital Texas Oil Index , ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OILT#NYSE">OILT</a>).
Price Action: BP shares are down 4.72% at $29.86 premarket at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44625332/bps-cypre-gas-project-goes-live-boosting-upstream-growth-plans" target="_blank" rel="noreferrer noopener">BP&#8217;s Cypre Gas Project Goes Live, Boosting Upstream Growth Plans</a></li>
</ul>

Equities

Large Cap

Movers

OILT

BP Begins Hunt for New Chair As Elliott Management Pushes for Changes

Jefferies analyst Michael Sarcone downgrades Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) from Buy to Hold and lowers the price target from $8 to $2.

EDAP

Jefferies Downgrades Edap TMS to Hold, Lowers Price Target to $2

Chinese electric scooter company Niu Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) disclosed its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44642144/niu-technologies-provides-first-quarter-2025-sales-volume-update" rel="noreferrer noopener">sales volume results for the first-quarter</a>.
In the first quarter, the company sold a total of 203,313 units, comprising e-motorcycles, e-mopeds, e-bikes, kick-scooters, and e-bikes.
Of these, 183,065 units were sold in China, while 20,248 units were sold in international markets.
Driven primarily by domestic momentum, Niu saw sales increase 57% in the first-quarter, from the 129,139 units sold in the same period last year.
The share of the growth came from the Chinese market, where Niu&#8217;s sales jumped 66% compared to the first-quarter of 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/44643859" rel="noreferrer noopener">Elon Musk, Mark Zuckerberg And Jensen Huang See $34 Billion Wiped Out In A Single Day: Here&#8217;s How Much Other &#8216;Magnificent 7&#8217; Billionaires Lost After Trump&#8217;s Liberation Day</a>
The company attributed the spike to its refreshed product line. The launch of its NX Pro model in late March was a standout success, drawing over 3.5 million live viewers and generating a flood of pre-orders in both online and offline channels.
International sales also edged higher by 6% year-over-year. Niu highlighted advances in its overseas electric motorcycle and micro mobility segments, indicating a broader market penetration throughout 2025.
Recently, Niu reported a 71.1% jump in fourth-quarter revenue to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44350753/niu-technologies-announces-unaudited-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">819.2&nbsp;million Chinese yuan&nbsp;($112.23 million)</a>.
The company expects first-quarter revenues&nbsp;to grow&nbsp;25% to 40% and sales volume of 1.3 million to 1.6 million units in 2025, a 40% to 70% increase on year.
NIU&#8217;s current product range is divided into two main categories, each featuring a variety of vehicle types. The first includes electric motorcycles, mopeds, and bicycles, such as the NQi, MQi, UQi, FQi series, among others.
The second category focuses on micro-mobility solutions, which consist of the KQi kick-scooter lineup and the BQi electric bike series.
Price Action: NIU shares traded lower by 16% at $3.21 in premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44630305/ai-powered-pizza-papa-johns-taps-google-cloud-for-smarter-orders" target="_blank" rel="noreferrer noopener">AI-Powered Pizza? Papa Johns Taps Google Cloud For Smarter Orders</a></li>
</ul>

Trading Ideas

General

Niu Technologies Q1 Sales Volume Surge 57% On Solid China Demand

Janney Montgomery Scott analyst Michael Gaugler downgrades Middlesex Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSEX#NASDAQ">MSEX</a>) from Buy to Neutral.

MSEX

Janney Montgomery Scott Downgrades Middlesex Water to Neutral

Trump's administration has decided to back one of the key projects initiated by former President Joe Biden: the Lobito Corridor.
The transcontinental railway aims to link the resource-rich areas of the Democratic Republic of Congo (DRC) and Zambia to Angola's Atlantic port of Lobito. This project would fortify the West's <a target="_blank" href="https://www.benzinga.com/25/02/43492445/critical-metal-demand-to-triple-by-2030-but-demographics-pose-risks" rel="noreferrer noopener">critical minerals supply chain</a>, shifting the regional export preference toward the Atlantic.
James Story, the U.S. chargé d'affaires and acting ambassador to Angola, clarified America's dedication to the project while leading a diplomatic tour along the 835-mile rail line.
"We are here to show our commitment to these projects. We will continue working with our partners," he said to reporters, according <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-03/trump-administration-backs-african-lobito-rail-plan-envoy-says?srnd=phx-markets" rel="noreferrer noopener">to</a> Bloomberg's report.
The Lobito Corridor is a <a target="_blank" href="https://www.benzinga.com/markets/commodities/24/02/37074505/african-rail-projects-become-battleground-for-us-china-competition-in-strategic-mineral-suppl" rel="noreferrer noopener">collaborative effort</a> involving the U.S., the European Union, and a group of private sector partners led by the commodities giant Trafigura.
Together, they plan to upgrade and expand the railway network to boost exports of copper and cobalt—key minerals needed for electric vehicles, AI data centers, and the global energy transition.
President Biden had promoted the corridor as part of a fresh approach to U.S.-Africa relations, focusing on commercial partnerships instead of traditional aid.
His administration had pledged nearly $4 billion for infrastructure, mining, and agriculture projects along the route. Although a hurricane delayed his only trip to Africa, Biden visited Angola in December, marking his <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/24/10/41416913/bidens-farewell-to-africa-strategic-motives-behind-first-and-only-presidential-visit" rel="noreferrer noopener">first and last visit to the continent</a>, cementing the project's importance in his foreign policy legacy.
The fresh endorsement from Trump's administration hints at an investment-driven diplomacy in Africa. Despite the tariffs affecting Angola, Zambia, and the DRC, the White House made it clear that there are exemptions for essential minerals.
Adam Cortese, the CEO of U.S.-backed solar company Sun Africa, is optimistic about this trend. "There definitely seems to be a growing push for the U.S. to compete more with China," he said <a target="_blank" href="https://www.nytimes.com/2025/04/02/world/africa/trump-angola-lobito-corridor.html" rel="noreferrer noopener">for</a> the New York Times, pointing to the increasing interest in backing American businesses in Africa.
The Lobito Corridor is also part of a larger strategy for the U.S. in the region. Zambia is ramping up copper production, targeting <a target="_blank" href="https://www.benzinga.com/markets/commodities/24/04/38115830/zambia-mining-boom-the-road-to-1-million-tons-of-copper" rel="noreferrer noopener">one million tons</a>, led by large foreign firms like First Quantum Minerals (OTCPK: FQVLF), Barrick (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>), and Glencore (OTCPK: GLCNF).&nbsp;&nbsp;
Meanwhile, discussions are underway for multibillion-dollar investments in the DRC's mining, and officials are investigating a possible <a target="_blank" href="https://www.benzinga.com/25/03/44216408/dr-congo-explores-a-minerals-for-security-deal-with-the-us" rel="noreferrer noopener">minerals-for-security deal</a> amid ongoing conflicts.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44636869/jp-morgan-turns-to-europe-sees-value-in-emea-mining-equities" target="_blank" rel="noreferrer noopener">JPMorgan Turns Bullish On European Miners, Sees Copper Rally As Key Catalyst</a></li>
</ul>
Photo via Shutterstock

Government

Commodities

Politics

Legal

Markets

FQVLF

GLCNF

GOLD

Trump's Administration Backs Biden's Legacy Project To Secure African Resources

Needham analyst Laura Martin reiterates Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) with a Buy and maintains $21 price target.

Reiteration

Needham Reiterates Buy on Viant Technology, Maintains $21 Price Target

Earnings

Press Releases

Vistra Reports Third Quarter 2024 Results, Raises and Narrows 2024 Guidance, and Initiates 2025 Guidance

With 288% Growth This Year, Is the S&P 500's Rising Star Still Worth the Investment?

Offerings

Vistra Announces Private Offering of Senior Secured Notes

Vistra Prices Private Offering of $1.25 Billion of Senior Secured Notes

Dynegy and Homefield Energy Announce Recipients of the 2024 Energy Leadership Awards

Vistra Connects Two Utility-Scale Solar Facilities to Grid and Extends Operations of Baldwin Power Plant in Response to Reliability Concerns in MISO

Vistra Announces Expansion of its Board of Directors with the Appointment of Rob Walters

Vistra to Report Full Year and Fourth Quarter 2024 Results on Feb. 27, 2025

Dividends

Vistra Declares Dividend on Common Stock and Series A Preferred Stock

Vistra Reports Fourth Quarter and Full-Year 2024 Results

Altus Power

AleAnna

Central Puerto S.A. American Depositary Shares (each represents ten Common Shares)

Comments

Vistra

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL